Silo Pharma
Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions including PTSD, stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. They develop both conventional drugs and psychedelic formulations, leveraging licensed technology and IP from leading universities and researchers. The company aims to streamline drug development using the 505(b)(2) pathway, which may lower costs and accelerate approval, with a focus on innovative solutions for conditions like Alzheimer's, Fibromyalgia, and Stress-Induced Psychiatric Disorders.
Industries
Nr. of Employees
small (1-50)
Products
Selective intranasal 5‑HT4 receptor agonist formulation for PTSD/stress‑induced affective disorders (pre‑IND)
A selective, non‑psychedelic intranasal formulation targeting the 5‑HT4 receptor designed for nose‑to‑brain delivery to treat PTSD and stress‑induced affective disorders. Program has completed pre‑IND submission activities.
Subcutaneous time‑released ketamine‑based dissolvable implant for fibromyalgia (preclinical)
A ketamine‑based, subcutaneous dissolvable implant engineered for time‑released delivery to manage fibromyalgia and chronic pain, intended as a non‑opioid, self‑administered alternative to intravenous therapies.
Intranasal compound targeting Alzheimer's disease (preclinical)
A novel intranasal compound described as targeting two receptor molecules with preclinical evidence suggesting potential cognitive and memory improvement.
CNS homing peptide platform for Multiple Sclerosis (preclinical)
A peptide‑based targeting approach designed to home to damaged CNS tissue, particularly spinal cord lesions, to deliver therapeutic payloads and mitigate inflammation while reducing systemic toxicity.
Selective intranasal 5‑HT4 receptor agonist formulation for PTSD/stress‑induced affective disorders (pre‑IND)
A selective, non‑psychedelic intranasal formulation targeting the 5‑HT4 receptor designed for nose‑to‑brain delivery to treat PTSD and stress‑induced affective disorders. Program has completed pre‑IND submission activities.
Subcutaneous time‑released ketamine‑based dissolvable implant for fibromyalgia (preclinical)
A ketamine‑based, subcutaneous dissolvable implant engineered for time‑released delivery to manage fibromyalgia and chronic pain, intended as a non‑opioid, self‑administered alternative to intravenous therapies.
Intranasal compound targeting Alzheimer's disease (preclinical)
A novel intranasal compound described as targeting two receptor molecules with preclinical evidence suggesting potential cognitive and memory improvement.
CNS homing peptide platform for Multiple Sclerosis (preclinical)
A peptide‑based targeting approach designed to home to damaged CNS tissue, particularly spinal cord lesions, to deliver therapeutic payloads and mitigate inflammation while reducing systemic toxicity.
Services
Funding and conducting sponsored research in partnership with academic institutions to evaluate therapeutic candidates and mechanisms (example: sponsored study on psilocybin and inflammation).
Establishing licensing and collaboration agreements to acquire or advance therapeutic IP from academic and research partners, enabling accelerated regulatory pathways.
Funding and conducting sponsored research in partnership with academic institutions to evaluate therapeutic candidates and mechanisms (example: sponsored study on psilocybin and inflammation).
Establishing licensing and collaboration agreements to acquire or advance therapeutic IP from academic and research partners, enabling accelerated regulatory pathways.
Expertise Areas
- Psychedelic and traditional therapeutic development
- Formulation science (intranasal and implantable controlled‑release)
- Preclinical CNS and chronic pain research
- Biomarker‑guided therapeutic development
Key Technologies
- Intranasal nose‑to‑brain delivery
- Subcutaneous controlled‑release dissolvable implants
- CNS‑homing peptide targeting
- 5‑HT4 receptor agonist pharmacology